ArticlePediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology2026
Proton pump inhibitors modulate esophageal epithelial barrier function and crosstalk with eosinophils.
Article in Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Eosinophilic Esophagitis: Mechanisms of Disease and Approach to Treatment.Current allergy and asthma reports · 2026Review
- Proton pump inhibitors modulate esophageal epithelial barrier function and crosstalk with eosinophils.Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology · 2026Article
Corrections and comments
- Update of
Authors and funding
7 authors.
Funding
Abstract
backgroundEosinophilic esophagitis (EoE) is a chronic allergic disorder driven by type 2 inflammation, characterized by eosinophilic infiltration and esophageal epithelial abnormalities, including barrier dysfunction, basal cell hyperplasia, epithelial thickening, and loss of differentiation. Although proton pump inhibitor (PPI) therapy is frequently employed in the management of EoE and is known to reduce esophageal eosinophilia, improve barrier function, and exert anti-inflammatory effects, the precise mechanism by which PPIs modulate type 2 inflammation and epithelial integrity remains incompletely understood.
methodsAir-liquid interface culture of esophageal epithelial cells was used to investigate the impact of the PPI omeprazole on barrier integrity in IL-13-treated cultures. Epithelial chemokine secretion was assessed following stimulation with IL-13 and omeprazole, and eosinophil migration from healthy human donors was evaluated using 3 μm pore-sized transwells. A co-culture system of epithelial cells and eosinophils was used to examine chemokine secretion, eosinophil adhesion, and activation marker expression.
resultsOmeprazole treatment of IL-13-treated air-liquid interface (ALI) cultures restored barrier integrity compared with IL-13-treated ALI cultures and resulted in 186 differentially expressed genes. Omeprazole treatment reduced STAT6 phosphorylation, downregulated calpain 14 expression, and upregulated desmoglein-1 in IL-13-treated ALI samples. IL-13 treatment induced upregulation of Eotaxin-3, CXCL10, and periostin, which were downregulated by omeprazole. Eosinophils co-cultured with human esophageal epithelial cells in the presence of omeprazole had diminished CD11b, CD18, and CD69 expression compared to those cultured with IL-13 alone, and less eotaxin-3, CXCL10, CCL2, and CCL4 were recovered from the co-culture media.
conclusionOmeprazole diminished the effects of IL-13 in both the epithelial air-liquid interface model and eosinophil-epithelial co-cultures, alleviating barrier dysfunction, chemokine expression, and the upregulation of eosinophil adhesion markers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.